Table 1 Summary of best confirmed response^a and MRD-negative^b rates.

Variable	D-Rd (n = 281)	Rd (n = 276)	P
Overall response
No. with response	261	211
Rate, % (95% CI)	92.9 (89.2–95.6)	76.4 (71.0–81.3)	< 0.0001^c
Clinical benefit, n (%)^d	266 (94.7)	237 (85.9)
Best overall response, n (%)
CR or better	159 (56.6)	64 (23.2)	< 0.0001^c
Stringent CR^e	82 (29.2)	29 (10.5)
CR	77 (27.4)	35 (12.7)
VGPR or better	226 (80.4)	136 (49.3)	< 0.0001^c
VGPR	67 (23.8)	72 (26.1)
Partial response	35 (12.5)	75 (27.2)
Stable disease^f	18 (6.4)	59 (21.4)
Progressive disease	0 (0.0)	4 (1.4)
Response could not be evaluated	2 (0.7)	2 (0.7)
MRD negative (10⁻⁵)	n = 286	n = 283
n (%)	87 (30.4)	15 (5.3)	< 0.0001^g

Response was assessed according to the Uniform Criteria Consensus recommendations of the International Myeloma Working Group [17, 18]. The analysis included patients who had a confirmed diagnosis of MM and measurable disease at baseline or screening. In addition, patients had received at least one administration of trial treatment and had at least one disease assessment after the baseline visit.
MRD minimal residual disease, D-Rd daratumumab/lenalidomide/dexamethasone, Rd lenalidomide/dexamethasone, CI confidence interval, CR complete response, VGPR very good partial response.
^aResponse-evaluable population.
^bIntent-to-treat population.
^cP value was calculated using the Cochran–Mantel–Haenszel chi-square test.
^dClinical benefit includes all patients with minimal response, partial response, VGPR, CR, and stringent CR.
^eCriteria for a stringent CR include the criteria for a CR plus a normal free light-chain ratio and the absence of clonal plasma cells as assessed by immunohistochemical or immunofluorescence analysis or by flow cytometry.
^fIncludes patients who achieved a minimal response.
^gP value was calculated using the Fisher’s exact test.

Quick links

Search